Incorporation of Donor-derived Cell-free DNA Into Clinical Practice for Renal Allograft Management

Yasir Qazi,Anup Patel,Mark Fajardo,Sarah McCormick,Gordon Fehringer,Ebad Ahmed,Meenakshi Malhotra,Zachary P Demko,Paul R Billings,Hossein Tabriziani,Philippe Gauthier

Transplantation Proceedings（2021）

引用 4|浏览8

暂无评分

摘要

•Donor-derived cell-free DNA (dd-cfDNA) is a validated biomarker for active rejection (AR).•We investigated how dd-cfDNA may impact biopsy decisions in renal transplant recipients.•About one-fourth of biopsies ordered after assessment by traditional markers show AR.•We found a 64% rate of AR in biopsies ordered within 2 weeks of dd-cfDNA testing.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要